Vetigenics: Funding, Investors & Team (Oct 2026)
Vetigenics develops new immunotherapies for treating cancer and chronic conditions in dogs, which do not have harmful side effects. By using our fully canine phage display platform, we can quickly identify unique antibody fragments or CANIBODIES™ that can bind to any target antigen with high affinity and functionality. These CANIBODIES™ are created from canine genes without the need for expensive and time-consuming adaptations, and can easily be turned into various types of therapies. Our treatments are designed to be highly effective and non-immunogenic, a feat that is not possible with other methods. Vetigenics is currently moving three antibody products through development and plans to start clinical trials in dogs in the first quarter of 2021.
Vetigenics has raised $6.0M across 1 funding round on record, the most recent a Seed of $6.0M announced in Feb 2025.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vetigenics Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Vetigenics Funding Rounds
Vetigenics Founders and Leadership Team
No contact details are on record for this team yet.
Vetigenics Funding Compared to Other Biotechnology Startups
Vetigenics' latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vetigenics in Biotechnology and Philadelphia
Companies Similar to Vetigenics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Vetigenics Funding FAQs
What does Vetigenics do?
Vetigenics develops new immunotherapies for treating cancer and chronic conditions in dogs, which do not have harmful side effects. By using our fully canine phage display platform, we can quickly identify unique antibody fragments or CANIBODIES™ that can bind to any target antigen with high affinity and functionality. These CANIBODIES™ are created from canine genes without the need for expensive and time-consuming adaptations, and can easily be turned into various types of therapies. Our treatments are designed to be highly effective and non-immunogenic, a feat that is not possible with other methods. Vetigenics is currently moving three antibody products through development and plans to start clinical trials in dogs in the first quarter of 2021.
How much funding has Vetigenics raised?
Vetigenics has raised $6.0M across 1 round on record. The most recent is a Seed of $6.0M announced in Feb 2025.
When did Vetigenics last raise funding?
Vetigenics' most recent funding round on record is a Seed of $6.0M, announced in Feb 2025.
Who founded Vetigenics?
FundedIQ lists Adriann Sax (Founder) at Vetigenics.
Where is Vetigenics headquartered?
Vetigenics is based in Philadelphia, Pennsylvania, United States.
How many employees does Vetigenics have?
Vetigenics is in the 1-10 employee band.
How does Vetigenics' funding compare to other Biotechnology startups?
Vetigenics' latest round of $6.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Vetigenics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vetigenics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.